Oric Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 100
- Market Cap
- $704.7M
- Website
- http://www.oricpharma.com
- Introduction
Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.
ORIC Pharmaceuticals Announces Promising Early Data for ORIC-944 and Collaboration for ORIC-114
ORIC Pharmaceuticals reported encouraging early data from a Phase 1b trial of ORIC-944 combined with apalutamide in metastatic castration-resistant prostate cancer (mCRPC).
Unicycive and ORIC Pharmaceuticals Receive Buy Ratings Based on Promising Clinical Data
Unicycive Therapeutics' OLC shows promise in treating hyperphosphatemia by reducing pill burden and adverse events, potentially gaining FDA approval by June 2025.
© Copyright 2025. All Rights Reserved by MedPath